Table 1.
General characteristics of included studies.
| Author, year | Type of economic evaluation | Perspective | Sample | Comparison | Cost data | Model outcome | Horizon | Study funding Source |
|---|---|---|---|---|---|---|---|---|
| (Goldman et al., 2001) | Mutli-stage national probabilistic sample to assess state-level variation and simulation to estimate the effects across each state | Societal | Probabilstic sample of AIDS cases | Simulation based on Medicaid eligibility, ADAP eligibility, ADAP benefits | HCSUS sample and self-report data | Monthly expenditure on outpatient and inpatient care, ER visits, drug costs, full time labor force participation and earnings | Not specified | HRSA, NIH, AHRQ, RWJF |
| Goyal, Hu, et al., 2021 (Goyal et al., 2021)* | Agent-based stochastic model | US Health Care System | Overall HIV burden in US | Simulates the 5 types of Ryan White HIV/AIDS program | RWHAP and ADAP | HIV incidence for MSM, mortality rate, average life expectancy for low CD4, lifetime care costs | 50 years | HRSA |
| Goyal. Luca, et al., 2021 (Goyal et al., 2021)* | Agent-based stochastic model | US Health Care System | Overall HIV burden in US | Simulates the 5 types of Ryan White HIV/AIDs Program | RWHAP and ADAP | Proportion of people with HIV virally suppressed, deaths, cumulative health care costs, ICER, QALY | 50 years | HRSA |
| (Johri et al., 2002) | State transition model with Monte Carlo Simulations | State ADAPs | ADAP clients |
(1) “High efficacy”, (2) “Low efficacy” ADAP policy scenarios | AIDS Cost and Services Utilization Survey |
Projected life expectancy, cumulative healthcare costs, ICER, QALYs | Lifetime | CDC; NIAID; NIH; NIMH |
| (Pinkerton et al., 2013) | Transmission mathematical model | Societal | ADAP clients | ADAP clients | Kaiser Foundation ADAP Fact Sheet (2008 dollars) | Cost of reduction in new secondary cases each year for those who are ADAP clients (Net cost per QALY) |
Lifetime | NIH; RWJF |
| (Schackman et al., 2001) | Markov state-transition and microsimulation | Government/ payer and societal | People with HIV who present for medical care with CD4 counts of 500 | (1) Immediate ART, (2) ART initiated at CD4 count of 200 (3) no ART | AIDS Costs and Services Utilization Survey | Incidence of opportunistic infections, years of life, QALYs gained, lifetime costs | Lifetime | NIH |
| (Snider et al., 2016) | Ordinary least squares regression model and simulation |
State ADAPs | ADAP clients | ADAP Policies (income limit, medical requirements, enrollment cap, asset limits) | Literature Review (Staszewski et al., 1996, Freedberg et al., 2001) | ADAP clients served, survival benefits (QALYs and $), and cumulative healthcare costs | Lifetime | Bristol-Myers Squibb |
*Same modeling approach, reporting on different outcomes.
Abbreviations: ADAP – AIDS Drug Assistance Programs; RWHAP – Ryan White HIV-AIDS Program; QALY – Quality-adjusted life-year; ICER – Incremental cost-effectiveness ratio; CDC – Centers for Disease Control and Prevention; HRSA – Health Resources and Services Administration; NIH – National Institutes of Health; NIAID – National Institute of Allergy and Infectious Diseases; NIDA – National Institute on Drug Abuse, RWJF – Robert Wood Johnson Foundation; NIMH – National Institute on Mental Health. HCSUS - HIV Cost and Services Utilization Study.